Published in Antimicrob Agents Chemother on March 01, 2002
Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (2003) 2.01
Antimicrobial susceptibility patterns and characterization of clinical isolates of Staphylococcus aureus in KwaZulu-Natal province, South Africa. BMC Infect Dis (2006) 1.89
Evaluation of molecular typing methods in characterizing a European collection of epidemic methicillin-resistant Staphylococcus aureus strains: the HARMONY collection. J Clin Microbiol (2007) 1.85
Contemporary methicillin-resistant Staphylococcus aureus clones in Hong Kong. J Clin Microbiol (2005) 1.56
Methicillin-resistant Staphylococcus aureus in Spain: molecular epidemiology and utility of different typing methods. J Clin Microbiol (2009) 1.16
In vitro antibacterial activity of DX-619, a novel des-fluoro(6) quinolone. Antimicrob Agents Chemother (2005) 1.15
Increasing prevalence of methicillin-resistant Staphylococcus aureus causing nosocomial infections at a university hospital in Taiwan from 1986 to 2001. Antimicrob Agents Chemother (2004) 1.04
Antimicrobial stewardship program directed at broad-spectrum intravenous antibiotics prescription in a tertiary hospital. Eur J Clin Microbiol Infect Dis (2009) 1.04
Cooccurrence of predominant Panton-Valentine leukocidin-positive sequence type (ST) 152 and multidrug-resistant ST 241 Staphylococcus aureus clones in Nigerian hospitals. J Clin Microbiol (2009) 1.02
Unusually high prevalence of nosocomial Panton-Valentine leukocidin-positive Staphylococcus aureus isolates in Cape Verde Islands. J Clin Microbiol (2006) 1.00
Diagnostic PCR analysis of the occurrence of methicillin and tetracycline resistance genes among Staphylococcus aureus isolates from phase 3 clinical trials of tigecycline for complicated skin and skin structure infections. Antimicrob Agents Chemother (2006) 1.00
Methicillin-resistant Staphylococcus aureus prevalence: current susceptibility patterns in Trinidad. BMC Infect Dis (2006) 0.94
A comparative in vitro photoinactivation study of clinical isolates of multidrug-resistant pathogens. J Infect Chemother (2007) 0.93
Antibiotic susceptibility of Staphylococcus aureus in suppurative lesions in Lacor Hospital, Uganda. Afr Health Sci (2011) 0.93
Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model. Antimicrob Agents Chemother (2007) 0.91
The efficacy and safety of linezolid and glycopeptides in the treatment of Staphylococcus aureus infections. PLoS One (2013) 0.83
In vitro and in vivo antibacterial activities of DW-224a, a new fluoronaphthyridone. Antimicrob Agents Chemother (2006) 0.82
Hospital-acquired infections in a Nigerian tertiary health facility: An audit of surveillance reports. Niger Med J (2011) 0.81
Staphylolysin is an effective therapeutic agent for Staphylococcus aureus experimental keratitis. Graefes Arch Clin Exp Ophthalmol (2011) 0.80
In vitro screening antibacterial activity of Bidens pilosa Linné and Annona crassiflora Mart. against oxacillin resistant Staphylococcus aureus (ORSA) from the aerial environment at the dental clinic. Rev Inst Med Trop Sao Paulo (2014) 0.79
Urinary tract infection among symptomatic outpatients visiting a tertiary hospital based in midwestern Nigeria. Glob J Health Sci (2013) 0.78
ANTIBIOTIC RESISTANCE PROFILING AND MICROBIOTA OF THE UPPER RESPIRATORY TRACT OF APPARENTLY HEALTHY DOGS IN IBADAN, SOUTH WEST NIGERIA. Afr J Infect Dis (2016) 0.75
In vitro characterization of representative clinical South African Staphylococcus aureus isolates from various clonal lineages. New Microbes New Infect (2014) 0.75
Methicillin-resistant Staphylococcus aureus nosocomial infection trends in Hospital Universiti Sains Malaysia during 2002-2007. Ann Saudi Med (2010) 0.75
Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother (1997) 17.36
Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA (1998) 15.66
The progressive intercontinental spread of methicillin-resistant Staphylococcus aureus. Clin Infect Dis (1997) 4.81
Bacterial pathogens isolated from patients with bloodstream infection: frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997). Antimicrob Agents Chemother (1998) 3.45
Methicillin-resistant Staphylococcus aureus in tertiary care institutions on the Canadian prairies 1990-1992. Infect Control Hosp Epidemiol (1994) 3.27
Nosocomial methicillin-resistant and methicillin-susceptible Staphylococcus aureus primary bacteremia: at what costs? Infect Control Hosp Epidemiol (1999) 2.69
Methicillin-resistant Staphylococcal aureus evolution in Australia over 35 years. Microb Drug Resist (2000) 1.57
Evolution of resistance in Staphylococcus aureus in Australian teaching hospitals. Australian Group on Antimicrobial Resistance (AGAR). Med J Aust (1996) 1.26
MRSA in the community. N Z Med J (1996) 1.20
Emergence of methicillin-resistant Staphylococcus aureus as a community pathogen. Diagn Microbiol Infect Dis (2001) 1.06
Dissemination of new methicillin-resistant Staphylococcus aureus clones in the community. J Clin Microbiol (2002) 10.88
Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis (2006) 7.36
Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int J Antimicrob Agents (2005) 4.71
Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations. J Infect Dis (2011) 3.98
Colistin hetero-resistance in multidrug-resistant Acinetobacter baumannii clinical isolates from the Western Pacific region in the SENTRY antimicrobial surveillance programme. J Infect (2008) 2.88
Stability of colistin and colistin methanesulfonate in aqueous media and plasma as determined by high-performance liquid chromatography. Antimicrob Agents Chemother (2003) 2.42
Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate. J Antimicrob Chemother (2004) 2.36
Use of high-performance liquid chromatography to study the pharmacokinetics of colistin sulfate in rats following intravenous administration. Antimicrob Agents Chemother (2003) 2.30
Guidelines for the diagnosis and antimicrobial therapy of canine superficial bacterial folliculitis (Antimicrobial Guidelines Working Group of the International Society for Companion Animal Infectious Diseases). Vet Dermatol (2014) 2.12
Regional variation in the prevalence of extended-spectrum beta-lactamase-producing clinical isolates in the Asia-Pacific region (SENTRY 1998-2002). Diagn Microbiol Infect Dis (2005) 2.04
Simple method for assaying colistin methanesulfonate in plasma and urine using high-performance liquid chromatography. Antimicrob Agents Chemother (2002) 2.02
Elucidation of the pharmacokinetic/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models. Antimicrob Agents Chemother (2009) 1.83
Prevalence of extended spectrum beta-lactamase (ESBL)-producing clinical isolates in the Asia-Pacific region and South Africa: regional results from SENTRY Antimicrobial Surveillance Program (1998-99). Diagn Microbiol Infect Dis (2002) 1.83
Comparison of once-, twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: studies with Pseudomonas aeruginosa in an in vitro pharmacodynamic model. J Antimicrob Chemother (2008) 1.75
Emergence and widespread dissemination of OXA-23, -24/40 and -58 carbapenemases among Acinetobacter spp. in Asia-Pacific nations: report from the SENTRY Surveillance Program. J Antimicrob Chemother (2008) 1.74
Methicillin-resistant Staphylococcus aureus in the Australian community: an evolving epidemic. Med J Aust (2006) 1.73
In vitro pharmacodynamics of colistin against multidrug-resistant Klebsiella pneumoniae. J Antimicrob Chemother (2008) 1.66
Consistent global approach on reporting of colistin doses to promote safe and effective use. Clin Infect Dis (2013) 1.56
Carbapenem resistance among Pseudomonas aeruginosa strains from India: evidence for nationwide endemicity of multiple metallo-beta-lactamase clones (VIM-2, -5, -6, and -11 and the newly characterized VIM-18). Antimicrob Agents Chemother (2008) 1.50
Carbapenem-resistant isolates of Klebsiella pneumoniae in China and detection of a conjugative plasmid (blaKPC-2 plus qnrB4) and a blaIMP-4 gene. Antimicrob Agents Chemother (2007) 1.46
Subacute toxicity of colistin methanesulfonate in rats: comparison of various intravenous dosage regimens. Antimicrob Agents Chemother (2008) 1.46
fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models. J Antimicrob Chemother (2010) 1.42
In-use efficacy of a chlorhexidine in alcohol surgical rub: a comparative study. ANZ J Surg (2004) 1.40
Vancomycin AUC/MIC ratio and 30-day mortality in patients with Staphylococcus aureus bacteremia. Antimicrob Agents Chemother (2013) 1.38
Antimicrobial resistance in Staphylococcus aureus in Australian teaching hospitals, 1989-1999. Microb Drug Resist (2003) 1.26
Antimicrobial susceptibilities of commonly encountered bacterial isolates to fosfomycin determined by agar dilution and disk diffusion methods. Antimicrob Agents Chemother (2011) 1.25
Zyvox Annual Appraisal of Potency and Spectrum program: linezolid surveillance program results for 2008. Diagn Microbiol Infect Dis (2009) 1.22
Evaluation of the contemporary occurrence rates of metallo-beta-lactamases in multidrug-resistant Gram-negative bacilli in Japan: report from the SENTRY Antimicrobial Surveillance Program (1998-2002). Diagn Microbiol Infect Dis (2004) 1.15
The urgent need for clear and accurate information on the polymyxins. Clin Infect Dis (2013) 1.13
Antimicrobial use guidelines for treatment of urinary tract disease in dogs and cats: antimicrobial guidelines working group of the international society for companion animal infectious diseases. Vet Med Int (2011) 1.12
Fusidic acid resistance rates and prevalence of resistance mechanisms among Staphylococcus spp. isolated in North America and Australia, 2007-2008. Antimicrob Agents Chemother (2010) 1.08
Stenotrophomonas maltophilia: emerging disease patterns and challenges for treatment. Expert Rev Anti Infect Ther (2011) 1.07
Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004). Int J Antimicrob Agents (2007) 1.05
Selective inhibition of biotin protein ligase from Staphylococcus aureus. J Biol Chem (2012) 1.03
The in vitro evaluation of tigecycline tested against pathogens isolated in eight countries in the Asia-Western Pacific region (2008). J Infect (2010) 1.03
aac(6')-Ib-cr genotyping by simultaneous high-resolution melting analyses of an unlabeled probe and full-length amplicon. Antimicrob Agents Chemother (2009) 1.02
Renal disposition of colistin in the isolated perfused rat kidney. Antimicrob Agents Chemother (2009) 1.02
Defining the dosage units for colistin methanesulfonate: urgent need for international harmonization. Antimicrob Agents Chemother (2006) 0.98
Contemporary antimicrobial activity of triple antibiotic ointment: a multiphased study of recent clinical isolates in the United States and Australia. Diagn Microbiol Infect Dis (2006) 0.96
3: Community-acquired pneumonia. Med J Aust (2002) 0.96
Impact of ethnicity and socio-economic status on Staphylococcus aureus bacteremia incidence and mortality: a heavy burden in Indigenous Australians. BMC Infect Dis (2012) 0.93
Prevalence of antimicrobial resistance in Enterococcus isolates in Australia, 2005: report from the Australian Group on Antimicrobial Resistance. Commun Dis Intell Q Rep (2007) 0.92
Molecular epidemiology of enterococcal bacteremia in Australia. J Clin Microbiol (2014) 0.90
Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolates. Antimicrob Agents Chemother (2009) 0.89
Spectrum and potency evaluation of a new oxazolidinone, linezolid: report from the SENTRY Antimicrobial Surveillance Program, 1998-2000. Diagn Microbiol Infect Dis (2002) 0.87
Minim typing--a rapid and low cost MLST based typing tool for Klebsiella pneumoniae. PLoS One (2012) 0.85
Multicentre evaluation of the in vitro activity of linezolid in the Western Pacific. J Antimicrob Chemother (2003) 0.85
Plasmid-borne blaSHV genes in Klebsiella pneumoniae are associated with strong promoters. J Antimicrob Chemother (2009) 0.84
Regional resistance surveillance program results for 12 Asia-Pacific nations (2011). Antimicrob Agents Chemother (2013) 0.84
Resistance development in community-acquired strains of methicillin-resistant Staphylococcus aureus: an in vitro study. Int J Antimicrob Agents (2004) 0.83
Doripenem activity tested against a global collection of Enterobacteriaceae, including isolates resistant to other extended-spectrum agents. Diagn Microbiol Infect Dis (2009) 0.81
A community-based intervention to reduce antibiotic use for upper respiratory tract infections in regional South Australia. Med J Aust (2005) 0.80
In vitro assessment of gatifloxacin spectrum and potency tested against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae isolates from the Asia-Western Pacific component of the SENTRY antimicrobial surveillance program (1998-1999). Diagn Microbiol Infect Dis (2002) 0.78
Codetection of blaOXA-23-like gene (blaOXA-133) and blaOXA-58 in Acinetobacter radioresistens: report from the SENTRY antimicrobial surveillance program. Antimicrob Agents Chemother (2008) 0.78
Activity of a peptide deformylase inhibitor LBM415 (NVP PDF-713) tested against recent clinical isolates from Japan. J Antimicrob Chemother (2005) 0.78
High burden of staphylococcal disease in indigenous communities. J Infect Dis (2009) 0.78
Antimicrobial activity and spectrum of daptomycin: results from the surveillance program in Australia and New Zealand (2008). Pathology (2010) 0.76
Development of a disk diffusion method for testing Moraxella catarrhalis susceptibility using clinical and laboratory standards institute methods: a SENTRY antimicrobial surveillance program report. J Clin Microbiol (2009) 0.75
Response to letter from J Mottet "Comments on the ISCAID Guidelines on the use of antimicrobial therapies in canine superficial bacterial folliculitis". Vet Dermatol (2014) 0.75
An interventional program for diagnostic testing in the emergency department. Med J Aust (2003) 0.75
Infectious complications of traditional Samoan tattooing. J Infect (2005) 0.75
Cross-border patients with tuberculosis. Med J Aust (2011) 0.75
In vitro potency of doripenem tested against an international collection of rarely isolated bacterial pathogens. Diagn Microbiol Infect Dis (2009) 0.75
Antimicrobial Use and Resistance in Australia (AURA) surveillance system: coordinating national data on antimicrobial use and resistance for Australia. Aust Health Rev (2017) 0.75
Gentamicin and ototoxicity: why this drug is still in use. Med J Aust (2012) 0.75